Phase III Study Showed Tarceva In Combination With Avastin As First-Line Maintenance Therapy Improved Progression-Free Survival In Advanced Lung Cancer

News — By on February 27, 2009 at 3:26 am

Genentech, Inc. announced that a Phase III study (ATLAS) of Tarceva (erlotinib) in combination with Avastin (bevacizumab) as maintenance therapy following initial treatment with Avastin plus chemotherapy in advanced non-small cell lung cancer (NSCLC) met its primary endpoint. The study was stopped early on the recommendation of an independent data safety monitoring board after a pre-planned interim analysis showed that combining Tarceva and Avastin significantly extended the time patients lived without their disease advancing, as defined by progression-free survival (PFS), compared to Avastin plus placebo. A preliminary safety analysis showed adverse events were consistent with previous Avastin or Tarceva studies, as well as trials evaluati…

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback